Helicobacter pylori is a small, curved, microaerophilic, gram-negative, rod-shaped bacterium that is recognized as one of the most common chronic bacterial infections worldwide. According to the Centers for Disease Control, approximately two-thirds of the global population is infected with H pylori, with a higher prevalence in developing countries. While H pylori infection is often asymptomatic, it is a major cause of peptic ulcer disease and gastritis worldwide. Symptoms of H pylori infection typically manifest as gnawing or burning epigastric pain, with less common symptoms including loss of appetite, nausea, or vomiting.
Designated as a carcinogen by the World Health Organization, H pylori infection is the strongest known risk factor for non-cardia gastric adenocarcinoma. Infected individuals have a 2–6-fold increased risk of developing gastric cancer and mucosal associated-lymphoid-type (MALT) lymphoma compared to their uninfected counterparts.
In this analysis, we have compared the guidelines provided by the World Gastroenterology Organisation (WGO) and the American College of Gastroenterology (ACG) regarding the management and treatment of H pylori. By juxtaposing these recommendations, our goal is to equip healthcare professionals with valuable insights and optimal strategies for evaluating and treating this condition. This evidence-based approach aims to enhance patient outcomes by facilitating early detection and appropriate intervention, while also balancing the risks of malignancy with the necessary follow-up care.
Titles of Comparison:
| Titles | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection | Helicobacter pylori |
|---|---|---|
| Society | American College of Gastroenterology (ACG) | World Gastroenterology Organisation (WGO) |
| Publication Date | September 4, 2024 | April 30, 2021 |
| Objective | The American College of Gastroenterology commissioned this clinical practice guideline (CPG) to inform the evidence-based management of patients with H. pylori infection in North America. | The purpose of this update to the WGO guideline is to summarize and review the evidencefrom a number of new guidelines that outline best practice and to suggest how theseprinciples may be applied around the world using the “cascades” approach. |
| Target Population | Target audience includes gastroenterologists, primary care physicians, internists, and pharmacists involved in diagnosing and treating H. pylori infection. | Target audience includes gastroenterologists, general practitioners, healthcare providers in low-resource settings, and global health practitioners involved in the management and treatment of H. pylori infection. |
| Methodology | This CPG used Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology to systematically analyze 11 Population, Intervention, Comparison, and Outcome questions and generate recommendations. | WGO Guidelines go through a rigorous process of authoring, editing, and peer review and are as evidence based as possible. Ultimate responsibility and editorial control lies with the WGO Guidelines Committee. |
| Graded Strength of Recommendations | Yes | Yes |
| Graded Level of Evidence | Yes | Yes |
| Systematic Review Conducted | Yes | Yes |
| Literature Review Conducted | Yes | Yes |
| COIs & Funding Source(s) Disclosed | Yes | Yes |
| Full-text | Treatment of Helicobacter pylori Infection | Helicobacter pylori |
| Summary | Summary | Summary |
Comparison of Key Points
| Category | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection | World Gastroenterology Organisation (WGO) Guidelines on Helicobacter pylori |
|---|---|---|
| Geographic Focus | Primarily the United States | Global (with emphasis on regions with high H pylori prevalence, including low-resource settings) |
| Treatment Approaches | Emphasizes the use of quadruple therapy (eg, PPI, bismuth, antibiotics) and triple therapy (PPI, clarithromycin, and amoxicillin or metronidazole) for H pylori eradication | Recommends combination therapy (PPI and antibiotics) with regional adaptations for the type of antibiotics used based on resistance patterns |
| Antibiotic Resistance Consideration | Acknowledges growing antibiotic resistance and recommends sensitivity testing if needed | Strong emphasis on adapting therapy based on local antibiotic resistance patterns |
| Helicobacter pylori Eradication Success Rates | Focuses on optimizing treatment regimens to achieve high eradication rates (eg, >90%) | Addresses challenges in eradication due to resistance and suggests treatment duration and regimen modifications based on regional resistance data |
| First-Line Therapy | Triple therapy (PPI, clarithromycin, and either amoxicillin or metronidazole) or quadruple therapy (PPI, bismuth, tetracycline, metronidazole) | First-line therapy recommendations vary by region but typically include triple therapy (PPI + two antibiotics) or quadruple therapy, depending on resistance levels |
| Role of Testing | Recommends urea breath test, stool antigen test, or endoscopy with biopsy for confirmation of H pylori infection and post-treatment eradication | Recommends testing using non-invasive methods (urea breath test, stool antigen test) and endoscopy for cases with complications (e.g., ulcers or cancer suspicion) |
| Consideration of Special Populations | Specific recommendations for populations like pregnant women, children, and patients with peptic ulcers or gastric cancer risk | Focus on vulnerable populations in different regions, including children and those in resource-limited settings, with adaptations for local healthcare resources |
| Follow-up Post-Treatment | Recommends confirming eradication 4-6 weeks after treatment using a non-invasive test | Post-treatment testing is recommended in areas with high resistance and failure rates, with follow-up tailored to regional practice |
| Global Health Consideration | Primarily US-focused but acknowledges growing global resistance patterns | Focuses on the global burden of H pylori infection and challenges in resource-limited settings, with practical solutions for these regions |
| Additional Considerations | Recommends against empirical treatment without testing for H pylori unless there's a clear indication | Highlights the importance of region-specific guidelines to tackle H pylori resistance patterns globally |
Key Similarities:
- Both guidelines prioritize antibiotic therapy (triple or quadruple therapy) for the eradication of H pylori.
- Both recommend post-treatment testing to confirm eradication.
- Both stress the importance of adjusting treatment based on antibiotic resistance patterns.
Key Differences:
- The ACG guidelines are primarily focused on the US and emphasize evidence-based, standardized therapies.
- The WGO guidelines are global in scope, with specific adaptations for low-resource settings and regional resistance patterns. They offer guidance on more flexible treatment approaches based on local healthcare capabilities.
These guidelines complement each other, with the ACG providing detailed, evidence-based recommendations for clinical practice in the US, while the WGO offers broader, global guidance that can be tailored to various regions and healthcare settings.
Make sure to sign up for guideline alerts on guidelinecentral.com to stay up to date on all future side-by-side blogs and let us know if there is a topic you’d like to see compared on our next article!
Copyright © 2025 Guideline Central, All Rights Reserved.